The U.S. PRP and stem cell alopecia treatment market size was valued at USD 123.7 million in 2017 and is anticipated to exhibit a CAGR of 5.1% over the forecast period. Increase in the number of people suffering from alopecia and rising awareness and adoption of novel treatment procedures are some of the factors driving demand for these procedures.
Stem cell and platelet-rich plasma (PRP) therapies are considered as regenerative or biomedicines. They are minimally invasive and hence reduce the need for surgery. These therapies help stimulate, rebuild, and strengthen hair regrowth, instead of removing damaged tissue from the scalp. Increasing preference for minimally invasive procedures over surgeries is expected to boost the U.S. market.
Novel therapies for alopecia are preferred by dermatologists and patients over conventional drugs such as corticosteroids. Greater preference for these therapies arises from efficient and faster hair regrowth as compared to other corticosteroid treatments. Additionally, ease of administration of these novel therapies is expected to drive demand over the forecast period.
The platelet-rich plasma therapy segment accounted for 43.4% of the revenue in 2017 and is expected to register the highest CAGR of 5.5% from 2018 to 2025. PRP therapy poses a lower risk of rejection because it contains platelets derived from the patient’s body. Upon entry into the body, these platelets release various proteins such as transforming growth factor, platelet-derived growth, vascular endothelial growth factor, interleukin (IL) - 1, and epidermal growth factor and help stimulate hair regrowth. Even though the use of PRP injections for the treatment of alopecia is not approved by the U.S. FDA, this procedure accounted for the highest volume of treatments performed in 2017.
Stem cell therapy dominated the U.S. PRP and stem cell alopecia treatment market with a revenue share of 56.6% in 2017 and is expected to register a CAGR of 4.9% from 2018 to 2025. Stem cell therapies include the use of adipose tissues found near the abdomen or those derived from hair follicles and synthesized in laboratories. These stem cells are injected in the scalp where alopecia is prominent, thus stimulating hair regrowth.
Various clinical trials on the treatment of alopecia are still underway and hence no significant clinical evidence pertaining to the efficacy of these procedures is available. Physicians have identified the benefits of stem cell therapy for the treatment of alopecia, which shows positive hair regrowth in most patients. This is expected to drive demand for stem cell therapy in the U.S.
On the basis of end user, the market has been segmented into hospitals, dermatology clinics, and other centers. The dermatology clinic segment dominated the market with a revenue share of 85.0% in 2017. In 2017, hospitals accounted for a 4.0% revenue share, which was valued at USD 4.9 million. This can be attributed to high procedure costs in hospitals as compared to other alternatives. Thus, the number of PRP and stem cell procedures being performed in hospitals is expected to remain low as compared to dermatology clinics and other end-user segments over the forecast period.
Most of the treatments in the U.S. are done by dermatologists in their privately owned settings. For instance, according to the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), dermatologists treat 84.8 % of total alopecia patients in the U.S. This is slated to give the segment a significant boost over the forecast period.
The U.S. market consists of a large number of providers offering novel alopecia treatment options such as PRP and stem cell therapies. Clinics providing these therapies are present across the country, with the highest number of treatments being carried out in dermatology clinics.
Some of the key providers in the market are Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, PLC, Virginia Surgical Center, Hair Transplant Institute of Miami, and Colorado Surgical Center & Hair Institute.
Attribute |
Details |
Base year for estimation |
2017 |
Actual estimates/Historical data |
2013 - 2016 |
Forecast period |
2018 - 2025 |
Market representation |
Procedures, Revenue in USD Million and CAGR from 2018 to 2025 |
Country scope |
The U.S. |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2013 to 2025. For the purpose of this study, Grand View Research has segmented the U.S. PRP and stem cell alopecia treatment market report on the basis of treatment and end user:
Treatment Outlook (Procedures; Revenue, USD Million, 2013 - 2025)
Platelet Rich Plasma Injections
Stem Cell Therapy
End-User Outlook (Procedures; Revenue, USD Million, 2013 - 2025)
Hospitals
Dermatology Clinics
Others
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.